Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.550
+0.110 (2.48%)
At close: Oct 2, 2026, 4:00 PM EDT
4.540
-0.010 (-0.22%)
After-hours: Oct 2, 2026, 7:39 PM EDT
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $13.82M in the quarter ending June 30, 2026, with 38.15% growth. This brings the company's revenue in the last twelve months to $54.09M, up 22.56% year-over-year. In the year 2025, Aquestive Therapeutics had annual revenue of $44.55M, down -22.61%.
Revenue (ttm)
$54.09M
Revenue Growth
+22.56%
P/S Ratio
10.56
Revenue / Employee
$367,939
Employees
147
Market Cap
571.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.55M | -13.02M | -22.61% |
| Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
| Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
| Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
| Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
| Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
| Dec 31, 2019 | 52.61M | -14.82M | -21.98% |
| Dec 31, 2018 | 67.43M | 512.00K | 0.77% |
| Dec 31, 2017 | 66.92M | 15.13M | 29.22% |
| Dec 31, 2016 | 51.79M | 49.07M | 1,807.37% |
| Dec 31, 2006 | 2.72M | 592.00K | 27.89% |
| Dec 31, 2005 | 2.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Evotec SE | 819.47M |
| Collegium Pharmaceutical | 808.21M |
| Emergent BioSolutions | 770.20M |
| Pacira BioSciences | 746.16M |
| Ironwood Pharmaceuticals | 389.32M |
| Evolus | 316.49M |
| Canopy Growth | 206.77M |
AQST News
- 3 days ago - Aquestive Therapeutics appoints Daly to board of directors - TheFly
- 3 days ago - Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly - GlobeNewsWire
- 15 days ago - Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film - GlobeNewsWire
- 18 days ago - Aquestive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 23 days ago - Aquestive Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - Aquestive Therapeutics Earnings release: Q2 2026 - Filings